ALLMedicine™ Cutaneous Candidiasis Center
Research & Reviews 19 results
Archives of Disease in Childhood. Fetal and Neonatal Edit... Akutsu A, Otsubo Y et. al.
May 29th, 2021 - Congenital cutaneous candidiasis in one infant among a twin sibling pair.|2021|Akutsu A,Otsubo Y,Suzumura H,Yoshihara S,|
The Pediatric Infectious Disease Journal; Miras I, Vierge E et. al.
Feb 5th, 2021 - Congenital cutaneous candidiasis is an infrequent invasive fungal infection that usually appears in the first days of life. Extremely low birth weight infants are the most frequently affected. Classic presentation includes diffuse extensive erythe...
BMC Pediatrics; Minka BM, Sibetcheu T A et. al.
Mar 20th, 2020 - Auto-immune polyendocrinopathy syndrome type I is a rare genetic disease, usually revealed by chronic superficial candidiasis and autoimmune endocrine dysfunction in childhood. We report the cases of 2 children, a 4 years-11 months old boy and 13 ...
Dermatologic Therapy; Muscianese M, Magri F et. al.
Feb 6th, 2020 - Jarisch-Herxheimer reaction (JHR) is an acute and self-limited condition, which commonly occurs after treatment for spirochetal infections. Probably, it corresponds to a transient immunological reaction to endotoxin-like products released from the...
Lasers in Surgery and Medicine; Leanse LG, Goh XS et. al.
Nov 21st, 2019 - Candida albicans is an opportunistic fungal pathogen of clinical importance and is the primary cause of fungal-associated wound infections, sepsis, or pneumonia in immunocompromised individuals. With the rise in antimicrobial resistance, it is bec...
Drugs 82 results see all →
News 3 results
Oct 31st, 2017 - Infants at a few weeks of life may present with a noncomedonal pustular eruption on the cheeks, forehead, and scalp commonly known as neonatal acne or neonatal cephalic pustulosis. The driving factor is thought to be an abnormal response to Malass.
Michele Khurana, MD, Jonathan S. Leventhal, MD et. al.
Jun 6th, 2017 - The Diagnosis: Langerhans Cell Histiocytosis Langerhans cell histiocytosis (LCH) is a clonal proliferative disorder of Langerhans cells that can affect any organ, most commonly the skin and bones. It typically develops in children aged 1 to 3 year.
Sep 30th, 2015 - Action Points The interleukin (IL)-17A inhibitor secukinumab was significantly more effective than placebo in the treatment of psoriatic arthritis in a phase III study, a finding that supported IL-17A as a therapeutic target in this disorder. Note...